NurExone Biologic Inc. (TSXV:NRX)
Canada · Delayed Price · Currency is CAD | Market Cap | 65.14M +4.4% |
| Revenue (ttm) | n/a |
| Net Income | -9.03M |
| EPS | -0.11 |
| Shares Out | 93.06M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 24,234 |
| Open | 0.6900 |
| Previous Close | 0.7000 |
| Day's Range | 0.6200 - 0.6900 |
| 52-Week Range | 0.4350 - 1.1400 |
| Beta | 0.39 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 31, 2026 |
About NurExone Biologic
NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It offers ExoPTEN, for treatment of acute spinal cord injuries. The company was founded in 2020 and is based in Toronto, Canada. [Read more]
News
NurExone Announces Closing of C$1,066,078 Private Placement
TORONTO, and HAIFA, Israel, Aug. 21, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome...
NurExone Reports New Preclinical Tissue-Analysis Data Supporting Potential Neuroprotective Effect of ExoPTEN in Acute Spinal Cord Injury Animal Model
Tissue analysis showed significantly higher numbers of myelin-positive cells in ExoPTEN-treated animals compared with controls, providing additional preclinical biological support for previously repor...
NurExone's Exo-Top Signs Binding MOU With Made Scientific For U.S. GMP Exosome Manufacturing
(RTTNews) - NurExone Biologic Inc. (NRX.V, NRXBF) announced that its U.S. subsidiary, Exo-Top Inc has signed a binding memorandum of understanding with Made Scientific, Inc to establish an exclusive U...
NurExone Announces Binding MOU with Made Scientific for U.S. GMP Manufacturing and Commercial Supply Partnership
The Signed MOU Targets Initial GMP Exosome Batches in H1 2027 to Support NurExone's Clinical Pipeline and Planned Commercial Production The Signed MOU Targets Initial GMP Exosome Batches in H1 2027 to...
NurExone Launches Bioprocess Optimization Initiative to Support Commercial and Clinical Readiness
TORONTO and HAIFA, Israel, July 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF, FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exosome-based ...
Corporate Updates – NurExone appoints Mr. David Stolick to the Board of Directors
TORONTO, Ontario and HAIFA, Israel, July 29, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing...
NurExone Announces Closing of Non-Brokered Private Placement
TORONTO, Ontario and HAIFA, Israel, June 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing...
Exo-Top, NurExone's wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in Mexico
TORONTO, Ontario and HAIFA, Israel, June 25, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing...
NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update
TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing...
Water Tower Research Publishes Initiation of Coverage Report on NurExone Biologic, Inc., “A Novel Exosome Therapy Platform at the Frontier of CNS Regeneration”
May 21, 2026, ST. PETERSBURG, FL – Water Tower Research (www.watertowerresearch.com) has published an Initiation of Coverage Report on NurExone Biologic, Inc. (TSXV: NRX/OTCQB: NRBXF) titled, “A Novel...
NurExone Receives Notice of Patent Grant in South Korea Covering ExoPTEN Technology
Expands intellectual property protection in a strategically important market for the Company's lead exosome-based therapy targeting nerve repair and functional recovery Expands intellectual property p...
NurExone Advances to Stage 2 of EU-Backed EIT Health Catapult Programme 2026
TORONTO, Ontario and HAIFA, Israel, May 14, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing ...
Australian Patent Granted to NurExone Covering Stem Cell-Derived Exosome Production
Sheba medical center researcher to present NurExone's exosome optic nerve regeneration work at ISCEV@Denver Sheba medical center researcher to present NurExone's exosome optic nerve regeneration work ...
NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update
TORONTO, Ontario and HAIFA, Israel, April 16, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biopharmaceutical company developin...
NurExone to Participate in Water Tower Research Insights Conference on April 14, 2026
Toronto, Ontario and Haifa, Israel--(Newsfile Corp. - April 10, 2026) - NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biotechnology company developing e...
NurExone Biologic's U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization
TORONTO, Ontario and HAIFA, Israel and POMPANO BEACH, Florida, April 07, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) and BioXtek...
NurExone Receives First Place in Healthcare at BOLD Awards VII and Engages Investor Brand Network to Support Awareness Strategy
TORONTO and HAIFA, Israel, April 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exosome-bas...
NurExone Strengthens U.S. Manufacturing Strategy Through Exo-Top Sublicense Agreement
Exo-Top Inc. positioned as a strategic U.S. subsidiary supporting manufacturing, clinical advancement and long-term value creation Exo-Top Inc. positioned as a strategic U.S. subsidiary supporting man...
NurExone Announces Corporate Updates
Consulting Agreement with Former Bayer Principal Scientist, BOLD Awards Healthcare Finalist Status, and Private Placement Closing Consulting Agreement with Former Bayer Principal Scientist, BOLD Award...
NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update
TORONTO and HAIFA, Israel, Feb. 27, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-...
NurExone Biologic Advances Manufacturing and Regulatory Roadmap with Independent Batch Consistency Results for Exosome Production
Toronto, Ontario and Haifa, Israel--(Newsfile Corp. - February 10, 2026) - NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biopharmaceutical company devel...
NurExone Appoints Eyal Gabbai to Board, Adding Large-Scale Healthcare System and Capital Markets Expertise
TORONTO and HAIFA, Israel, Jan. 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) today announced changes to its board of director...
NurExone Reports Anti-Inflammatory Activity of Its Exosomes in Lab Analysis
Reducing inflammation helps create a regenerative environment in the Central Nervous System Reducing inflammation helps create a regenerative environment in the Central Nervous System
NurExone Plans Small-Scale of ExoPTEN Clinical Manufacturing in Preparation for FUTURE First in Human USE Pathways
Supported by Scientific Evidence Showing Tissue Repair Quality of Company's Exosomes Supported by Scientific Evidence Showing Tissue Repair Quality of Company's Exosomes
NurExone Biologic Inc. Announces Third Quarter 2025 Financial Results and Provides Corporate Update
TORONTO and HAIFA, Israel, Nov. 28, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company pione...